학술논문
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
Document Type
Correspondence
Author
Source
In Annals of Oncology June 2021 32(6):817-819
Subject
Language
ISSN
0923-7534